. 2022 Jun 17;13:909275. doi: 10.3389/fimmu.2022.909275

Table 2.

Overview of DMTs for MS influencing ILCs.

Drug	Mechanism	ILC type	Effects on ILCs
Interferon beta 1a	Reduction of T-cell proliferation (47) Reduction of MHC class II molecule expression (47) Lowered IFN-β production by Th17 cells (47)	NK cells	Upregulation of MHC class I dampened cytotoxicity of CD56^dim NK cells (47) Altered CD56^dim/CD56^bright population ratio with an expansion of CD56^bright NK cells (48, 49)
Natalizumab	Humanized alpha 4 integrin antibody inhibiting leukocyte migration (50)	NK cells	Increase of total NK cell numbers (including CD56^bright NK cells) in the blood and reduced NK cell numbers in the CSF (50, 51)
**Daclizumab	Monoclonal antibody against IL2 receptor CD25 (52)	NK cells ILCs	Expansion of immunoregulatory CD56^bright NK cells in peripheral blood and CSF (51, 53) Decrease in circulating ILCs and shift in LTi phenotype towards NK lineage (43)
Alemtuzumab	Monoclonal antibody specific for the membrane glycoprotein CD52 (54)	NK cells	Expansion of CD56^bright NK cells with no altered cytolytic function (54)
Dimethyl fumarate	Nrf2 activator with immunomodulating, anti-inflammatory and anti-oxidative effects (55)	NK cells	Expansion of CD56^bright NK cells (56) decrease in absolute numbers of CD56^dim cells (55)
Fingolimod	Sphingosine 1-phosphate receptor agonist (57)	NK cells ILCs 1-3	Decreased number of CD56^bright NK cells (55, 57, 58) CD56^dim NK cells are increased in the circulation (54, 58) Percentage of total NK cells increased (59) Interrupted ILC circulation in both humans and mice (3) -ILC2 migration blockade to lung or bone marrow in mice (60)

**has been withdrawn from the market in 2018.